Karyopharm Therapeutics Inc  

(Public, NASDAQ:KPTI)   Watch this stock  
Find more results for KPTI
-0.09 (-0.93%)
Real-time:   1:15PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.40 - 9.88
52 week 4.83 - 19.41
Open 9.77
Vol / Avg. 97,146.00/653,212.00
Mkt cap 358.06M
P/E     -
Div/yield     -
EPS -3.25
Shares 35.99M
Beta     -
Inst. own 63%
Sep 12, 2016
Karyopharm Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Sep 8, 2016
Karyopharm Therapeutics Inc at Robert W Baird Global Healthcare Conference
Sep 6, 2016
Karyopharm Therapeutics Inc on Phase 2b STORM study and the planned development path for selinexor (KPT-330) in multiple myeloma (MM) Results Call - Webcast
Aug 17, 2016
Karyopharm Therapeutics Inc at Wedbush PacGrow Healthcare Conference
Aug 10, 2016
Karyopharm Therapeutics Inc at Canaccord Genuity Growth Conference
Aug 4, 2016
Q2 2016 Karyopharm Therapeutics Inc Earnings Release
Aug 4, 2016
Q2 2016 Karyopharm Therapeutics Inc Earnings Call
Jul 13, 2016
Karyopharm Therapeutics Inc at Cantor Fitzgerald Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -51115.25% -47234.00%
Operating margin -51654.24% -47630.40%
EBITD margin - -47376.80%
Return on average assets -66.64% -54.19%
Return on average equity -73.18% -58.29%
Employees 105 -
CDP Score - -


85 Wells Ave
NEWTON CENTER, MA 02459-3298
United States - Map
+1-617-6580600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

Officers and directors

Sharon Shacham Ph.D. President, Co-Founder, Chief Scientific Officer, Director
Age: 44
Bio & Compensation  - Reuters
Michael G. Kauffman M.D. Ph.D. Co-Founder, Chief Executive Officer and Director
Age: 52
Bio & Compensation  - Reuters
Justin A. Renz Chief Financial Officer, Executive Vice President, Treasurer
Age: 43
Bio & Compensation  - Reuters
Christopher B. Primiano Vice President- Corporate Development, General Counsel, Secretary
Age: 34
Bio & Compensation  - Reuters
Dilara McCauley Ph.D. Vice President - Product Leadership
Bio & Compensation  - Reuters
Brian Austad Ph.D. Senior Director, Head - Pharmaceutical Sciences
Bio & Compensation  - Reuters
Ran Frenkel Chief Development Operations Officer
Age: 46
Bio & Compensation  - Reuters
Barry E. Greene Lead Independent Director
Age: 52
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
Mansoor Raza Mirza M.D. Director and Clinical Advisor
Age: 54
Bio & Compensation  - Reuters